Lung cancer rates are dropping, but it remains the second-most-common cancer in both men and women (excluding skin cancer). About 14 percent of all new cancers are lung cancers, and most of those are NSCLC. But today, the outlook for patients is improving, in large part because immunotherapy is transforming the way cancers are treated.
Across cancer types, emerging new therapies are harnessing the immune system, with the PD-1/L1 inhibitor class at the forefront. Datamonitor reports an $18 billion opportunity within the PD-1/L1 inhibitor class of therapeutics. IO trial activity is especially intense in NSCLC: Trials evaluating PD-1/PD-L1 inhibitors represent 84% of all IO NSCLC trials.
Are you up to date on what’s happening in this space? Download your free Immuno-Oncology in Non-Small Cell Lung Cancer infographic below. At a glance, you will gain valuable insights into IO-NSCLC clinical activity. Among the questions it answers:
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: